Vida’s LungPrint solution uses AI to analyze inspiratory chest CT scans, automatically detecting abnormalities that can indicate emphysema or interstitial lung disease. UnityPoint Health Ventures’ investment will help Vida further develop and commercialize the platform, while the partnership will give Vida access to UnityPoint’s network of hospitals, clinics and medical experts to inform that development.
UnityPoint launched its $100 million venture fund in May, with a goal of backing early-stage companies in the areas of digital health, medical devices, healthcare technology systems and healthcare services. To date, in addition to Vida, the fund’s portfolio includes Health Catalyst and RxRevu.
More articles on AI:
Cincinnati Children’s AI system reduces patient screening time by 34 percent
Children’s National Health to apply AI to study ICU transitions
Microsoft invests $1B for development of superhuman AI
